EpiCept: Undervalued going into ASCO We are initiating coverage of EpiCept with a Speculative Buy recommendation and a two-month target of SEK 8,40 / USD 1,37 per share.Read moore!www.nordicbioinvestor.com/Analysis/NBI%20Insight%20-%20No%202%20-%2020.04.2011.pdf
Went down 35% from there with no pop at all, you are not very good at trading stocks are you?EPCT BK?DELIST?Which will come first???
Oh damn, you are ALL IN! too, classic. No wonder you are so bitter over at OXGN where you SHOULD have been all in back in May.
Look @ nr 14-15!http://www.nordicbioinvestor.com/Analysis/NBI%20Insight%20-%20No%202%20-%2020.04.2011.pdfALL IN!